/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png00h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2019-11-25 07:50:002019-11-25 07:50:00Arctoris: John Mattick on board
Roche AG said on Friday that its PD-L1 blocker Tecentriq plus its VEFG blocker Avastin improved progression-free survival versus sorafinib in a pivotal study in hepatocellular carcinoma (HCC) patients.
https://european-biotechnology.com/wp-content/uploads/2024/04/breast_cancer_NCI.jpg611600Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2019-11-22 05:59:002019-11-22 05:59:00Azeria Therapeutics bags €37.3m in Series B financing round
https://european-biotechnology.com/wp-content/uploads/2024/04/money-Nattanan_Kanchanaprat.jpg12811920Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2019-11-21 05:20:002019-11-21 05:20:00GHO capital launches EU’s largest fund ever for life sciences
Thicker than ever: The 21st edition of the Guide to German Biotech Companies has been published. Almost 120 companies from the vibrant biotech sector present themselves in the English-language yearbook.
Danish Novo Nordisk A/S has secured access to Dicerna Inc’s GalXC RNAi technology in a R&D deal worth US$225m upfront over three years comprising 30 liver targets.
The EU has made poor progress combatting antimicrobial resistance, a report from the European Court of Auditors (ECA) warns. Innovators need to be supported, urges the BEAM Alliance.
Researchers at French-US allogeneic CAR-T cell developer Cellectis SA have designed an engineered CAR-T cell that secretes IL-12 upon contact with tumour cells.
https://european-biotechnology.com/wp-content/uploads/2024/04/Cellectis.jpg310608Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2019-11-15 06:58:442019-11-15 06:58:44Cellectis presents way to safer CAR-Ts
Arctoris: John Mattick on board
AppointmentsJohn Mattick has been appointed to the Board of Directors of Oxford-based research company Arctoris Ltd.
Tecentriq-Avastin combo hits endpoint in liver cancer
Latest NewsRoche AG said on Friday that its PD-L1 blocker Tecentriq plus its VEFG blocker Avastin improved progression-free survival versus sorafinib in a pivotal study in hepatocellular carcinoma (HCC) patients.
Azeria Therapeutics bags €37.3m in Series B financing round
Latest NewsGHO capital launches EU’s largest fund ever for life sciences
Latest NewsGHO Capital raises €975m in largest ever European private equity healthcare fund.
Update: BIO-Europe growing further
Latest NewsEurope’s largest partnering event, the BIO-Europe, hit another visitor record on the occasion of its 25th anniversary in Hamburg.
Zelluna Immunotherapy and Glycostem Therapeutics in licence deal
Latest NewsZelluna Immunotherapy and Glycostem Therapeutics have partnered to develop allogeneic TCR-NK therapies.
Growing sector – growing guide
ProductsThicker than ever: The 21st edition of the Guide to German Biotech Companies has been published. Almost 120 companies from the vibrant biotech sector present themselves in the English-language yearbook.
Novo secures Dicerna’s RNAi liver assets
Latest NewsDanish Novo Nordisk A/S has secured access to Dicerna Inc’s GalXC RNAi technology in a R&D deal worth US$225m upfront over three years comprising 30 liver targets.
EU with poor success in fighting superbugs
Latest NewsThe EU has made poor progress combatting antimicrobial resistance, a report from the European Court of Auditors (ECA) warns. Innovators need to be supported, urges the BEAM Alliance.
Cellectis presents way to safer CAR-Ts
Latest NewsResearchers at French-US allogeneic CAR-T cell developer Cellectis SA have designed an engineered CAR-T cell that secretes IL-12 upon contact with tumour cells.